METOPROLOL TARTRATE | N219373 | RUBICON RESEARCH LTD
| Trial | Phase | Status | Sponsor | Enrollment | Dates |
|---|---|---|---|---|---|
| Phase 4 | Active | Bispebjerg Hospital | 2,760 | 2018-12-17 → 2035-12-10 | |
| Phase 4 | Active | Ole Frobert, MD, PhD | 1,713 | 2018-06-12 → 2026-04-30 | |
| N/A | Recruiting | Cedars-Sinai Medical Center | 150 | 2018-07-30 → 2026-12-31 | |
| Phase 4 | Completed | Bispebjerg Hospital | 50 | 2004-02 → 2007-10 | |
| Phase 4 | Completed | Recep Tayyip Erdogan University | 88 | 2015-07 → 2016-02 | |
| Phase 4 | Completed | Weill Medical College of Cornell University | 37 | 2009-10 → 2011-01 | |
| Phase 3 | Completed | The George Institute | 4,587 | 2012-03 → 2018-08 | |
| Phase 3 | Completed | University of Chicago | 72 | 2016-12 → 2023-08-29 | |
| Phase 4 | Completed | AstraZeneca | 252 | 2006-10 → 2009-01 | |
| Phase 4 | Completed | AstraZeneca | 251 | 2010-10 → 2011-09 |
Source: ClinicalTrials.gov. Trials matched by ingredient name.
13 active API suppliers hold Drug Master Files for this ingredient.
Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.
| Date | Submission | Document |
|---|---|---|
| Apr 16, 2025 | ORIG -1 | View Letter (PDF) |
Source: Drugs@FDA application documents.
No patent or exclusivity listings for this strength.